LMAT icon

LeMaitre Vascular

99.54 USD
-1.38
1.37%
At close Feb 21, 4:00 PM EST
After hours
99.54
+0.00
0.00%
1 day
-1.37%
5 days
2.72%
1 month
-0.11%
3 months
-5.98%
6 months
15.06%
Year to date
8.82%
1 year
59.80%
5 years
227.65%
10 years
1,177.79%
 

About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Employees: 630

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

78% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 23

25% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 95

24% more call options, than puts

Call options by funds: $332K | Put options by funds: $267K

4% more funds holding

Funds holding: 288 [Q3] → 300 (+12) [Q4]

0.07% more ownership

Funds ownership: 93.37% [Q3] → 93.44% (+0.07%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

1% less capital invested

Capital invested by funds: $1.95B [Q3] → $1.94B (-$12.4M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$95
5%
downside
Avg. target
$95
5%
downside
High target
$95
5%
downside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Wells Fargo
Nathan Treybeck
50% 1-year accuracy
2 / 4 met price target
5%downside
$95
Equal-Weight
Initiated
13 Feb 2025

Financial journalist opinion

Neutral
GlobeNewsWire
3 weeks ago
LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025
Negative
Seeking Alpha
3 weeks ago
The Most Underrated Mistake Destroying Your Retirement - December Dividend Income Report
Since its inception, my portfolio has been up 177%, with a 15% annualized growth rate. At this time, I'm thinking of adding a little bit more of Telus to this portfolio. The stock has been significantly penalized, while Telus' situation isn't that catastrophic (free cash flow and cash from operations improved throughout 2024). After selling Texas Instruments, the only stock I could see myself selling in 2025 would be BlackRock.
The Most Underrated Mistake Destroying Your Retirement - December Dividend Income Report
Positive
CNBC Television
1 month ago
Julie Biel shares her 2025 small cap picks
CNBC guest trader Julie Biel shares her 2025 small cap picks.
Julie Biel shares her 2025 small cap picks
Neutral
Zacks Investment Research
1 month ago
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport.
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
Neutral
GlobeNewsWire
2 months ago
LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes.
LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering
Neutral
CNBC Television
2 months ago
Final Trade: LMAT, GOOGL, IBM, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: LMAT, GOOGL, IBM, GILD
Positive
Zacks Investment Research
2 months ago
RMD vs. LMAT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either ResMed (RMD) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks?
RMD vs. LMAT: Which Stock Is the Better Value Option?
Neutral
GlobeNewsWire
2 months ago
LeMaitre to Participate at Upcoming Investor Conferences in December
BURLINGTON, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in December.
LeMaitre to Participate at Upcoming Investor Conferences in December
Positive
Seeking Alpha
3 months ago
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth.
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Neutral
GlobeNewsWire
3 months ago
LeMaitre to Participate at Upcoming Investor Conferences in November
BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November.
LeMaitre to Participate at Upcoming Investor Conferences in November
Charts implemented using Lightweight Charts™